Drug Profile
CMN 005
Alternative Names: CAR-CIK; Chimeric antigen receptor modified cytokine induced killer cell; CIK CAR.CD19; CIK-CAR CD19 immunotherapy - CoImmune; CMN-005Latest Information Update: 29 May 2023
Price :
$50
*
At a glance
- Originator University of Milan Bicocca
- Developer Fondazione Matilde Tettamanti; Formula Pharmaceutical
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Precursor cell lymphoblastic leukaemia-lymphoma
- Preclinical Non-Hodgkin's lymphoma
Most Recent Events
- 29 May 2023 Preclinical development in Non-Hodgkin's-lymphoma is ongoing in Italy (IV, Infusion)
- 22 May 2023 Fondazione Matilde Tettamanti Menotti De Marchi Onlus plans a phase I/II trial for Non-Hodgkin's lymphoma and Chronic lymphocytic leukaemia (Second-line therapy or greater, In adults, In neonates, In infants, In children, In adolescents) in September 2023 (NCT05869279)
- 28 Dec 2022 No recent reports of development identified for preclinical development in Non-Hodgkin's-lymphoma in Italy (IV, Infusion)